Clinical trial · Interventional
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma
NCT01408043CI-TRIAL-00039080terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accrual
Summary
Brief summary (as posted)
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
Conditions
Conditions (34)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia in Remission | Adult Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.78 |
| Adult Grade III Lymphomatoid Granulomatosis | Adult Grade III Lymphomatoid Granulomatosis | ONTOLOGY_EXACT | 0.98 |
| Adult Nasal Type Extranodal NK/T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Anaplastic Large Cell Lymphoma | Anaplastic Large Cell Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Angioimmunoblastic T-cell Lymphoma | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | ALIAS | 0.90 |
| Cutaneous B-cell Non-Hodgkin Lymphoma | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | ALIAS |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| leukapheresis | Procedure | — | UNRESOLVED |
| plerixafor | Drug | Plerixafor | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (stem cell supermobilization)
- description
- Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
- interventionNames
- Drug: plerixafor
- Biological: filgrastim
- Drug: etoposide
- Procedure: leukapheresis
Primary outcomes (3)
- measure
- Collection Using Plerixafor, Etoposide, and Filgrastim
- timeFrame
- Within 2 days of apheresis
- description
- Number of participants able to collect equal to or more than 8 x 10\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\^6 CD34+ cells/kg are defined as normal mobilizers.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 78 Years
Show eligibility criteria text
Inclusion Criteria: * Have biopsy-confirmed non-Hodgkin lymphoma, of any type * Must be eligible for autologous transplantation according to institutional guidelines * Eastern Cooperative Oncology Group performance status of 0 or 1 * Karnofsky performance status of 70 to 100 * Negative for human immunodeficiency virus (HIV) * prior to the start of mobilization, subjects must have: * Absolute neutrophil count of \>= 1.2 x 10\^9/L * Platelet count of \>= 100 x 10\^9/L * Creatinine clearance \>= 30 mL/minute * All patients must be able to comprehend and sign informed consent * If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy Exclusion Criteria: * Have had previous transplants and/or prior mobilization attempts * Have evidence of progressive non-Hodgkin lymphoma * Have evidence of bone marrow involvement of lymphoma at time of transplant staging * Had evidence of active central nervous system (CNS) involvement * Have had previous radiation of the pelvic area * Have had prior radioimmunotherapy * Have received experimental therapy within 2 weeks of enrollment * Be currently enrolled in another investigational protocol * Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
References
Publications (0)
Data not yet available
No reference posted for this study.